2015 & 14 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit & Exhibition

Transcription

1 2015 & 14 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit & Exhibition Managing critical challenges and opportunities in China s pharma & life science industry in a new era 16 th & 17 th April, 2015 Shanghai China Hear Latest Regulatory Changes from Previous & Priority Inviting Keynote Speakers National Health & Family Planning Commission China Food & Drug Administration National Development & Reform Commission Ministry of Human Resources & Social Security State Intellectual Property Office Supported by China Health Industry Association Harindra Ranil Abeysinghe Vice President, Head of Asia Pacific Regulatory Affairs, Pharmaceuticals Johnson & Johnson Helen Chui President China Novartis Alexander Hardy Head, Asia Pacific, Pharmaceuticals Roche Luke Miels Executive Vice President AstraZeneca Dr Jean-Luc Lowinski Senior Vice President Asia Sanofi Allan Gabor Managing Director China Merck Serono And many more Shanghai Health Industry Development & Promotion Association China s Most Premier Pharmaceutical Industry Event in 2015 Media Partners Network with over 150 pharma CEOs and senior health policy makers at the most successful pharmaceutical industry annual event in China Obtain first hand information on the latest healthcare reform, drug administrative changes, pricing, registration, reimbursement and other key policies in the pipeline Hear exclusive case studies on drug innovation, medical affairs, patient access, commercial operations, SFE and winning strategies for medicines in a variety of therapeutic areas Find the best solutions to your key challenges to prosper in the next 10 years Conference Roundtable Summit Visit us at

2 14 th Annual China Pharma, Life Science & Healthcare Industry Summit & Exhibition BACKGROUND Managing the Most Critical Challenges to the Pharmaceutical, Life Science and Healthcare Industry in a New Era China s pharmaceutical market has continued to experience pronounced and rapid expansion in recent years growing at 20% at average, nearly doubling every four years. Yet behind this picture of dynamic sales growth, hurdles remain for China s pharmaceuticals businesses. Industry consolidation, access to insurance, changing demographics and emerging issues brought by the new medical system reform will all alter the playing field in the next few years This is your best opportunity of the year to meet key officials and industry leaders to obtain first hand information on all the recent regulatory changes, new industry trends and successful business strategies for continuous growth and profitability in the industry. Do Not Miss It!! Why Participate in 2015 & 14 th Annual China Pharma, Life Science & Healthcare Industry Summit & Exhibition (CPHIS 2015)? Unique Meeting Place: CPHIS is the only and biggest get-together for high profile pharmaceutical & life science companies in China and the Asia Pacific region Increasing Your Profits: In response to market volatility and regulatory changes, CPHIS helps you find out and use cuttingedge strategies to drive competitive advance in your role for your business Connecting Industry Peers: CPHIS connects you with the top domestic and international pharma CEOs and policy makers among our speakers and delegates to create or revitalise your network of personal contacts Maximising Marketing Exposure: CPHIS 2015 is the most powerful and effective marketing platform targeting key decision makers from the pharma, life science and healthcare industries across the region. Who You Will Meet

3 14 th Annual China Pharma, Life Science & Healthcare Industry Summit & Exhibition DAY ONE Thursday 16 th April, Registration & Morning Tea Opening Address from the Chairman OPENING REMARK Changing Landscape of China s Pharmaceutical & Healthcare Industry: Insights, Trends, Facts and Further Changes What are we to expect in and beyond 2015 What impacts will the latest medical system reform, new drug administration policies including the GSK incident have on future business practices What opportunities/challenges is the rapidly diversifying business environment creating for different players: multinational vs. local Analysing growth potentials by key product types and segments under the impact of rapid industry changes KEYNOTE SESSION Exploring New Growth Models for Big Pharma in China: Finding New Directions for a New Generation What new business habits will emerge and how pharma business models will adapt under the new healthcare reform and stricter industry supervision Winning strategies in an era of cost containment New collaboration models in China Patented vs. generic medicines, retail pharmacies vs. hospital sales: how the healthcare market and pharma business model will evolve in next 5 years Growing beyond major cities - which internal cities offer the best prospect of long-term growth China strategy in a global context Morning Refreshment & Network Break REGULATORY ADDRESS China s Drug Registration, Administration & Key Enforcement Measures in 2015 Latest development and regulatory changes on drug administration New initiatives in clinical trial, new drug registration, drug approval and appraisal system in China The new GMP standard and changes in other GXP supervision measures Improvement and enforcement of national drug standards and electronic monitoring Other policies and measures in the pipeline China Food & Drug Administration Updating on EDL Development and Future Directions of Drug Reimbursment and Payment System Reform National Health & Family Planning Commission Ministry of Human Resources & Social Security CEO PANEL How to Reposition for Success in Difficult Times CEOs from Leading Pharmaceutical Companies Networking Lunch KEYNOTE SESSIONS Effectively Tackling the R&D Productivity Challenge Can an MNC in China address the challenges of global R&D Exploring new innovation models and innovative ways of drug discovery Successful China innovation strategy and implementation Integrated discovery and development process for a better pipeline and faster cycle-times How to build fruitful industry-academia and industry-biotech partnerships in China Effectively managing the integration of external research How to Overcome Barriers to Managing Medical Affairs and Clinical Trial Compliance in China How to overcome regulatory constraints to fasttrack clinical trials Managing early phase clinical trials in China to accelerate market penetration How to improve patient data management, patientphysician relationship, protocol compliance etc. to increase control of trial design and direction Aligning clinical development, medical affairs and regulatory affairs to enhance your clinical trial design Strategies for accelerating drug approval in China Regulatory Insight: Strategies to Accelerate Time to Market Understanding the CFDA Green Channel and parallel approval/review system for new drug applications and ethical committee evaluations Exploring effective strategies/approaches to accelerate development timeline and launch products more rapidly in China Latest Drug Safety Regulatory Changes and New Requirements on ADR Monitoring and Post-Market Surveillance China Food & Drug Administration Afternoon Refreshment & Networking Break FOCUS SESSION Managing Pharmaceutical Supply Chain and Cold Chain in China Latest GSP requirement updates How to improve your demand planning strategies in order to dramatically reduce costs Professional 3PL service platform for pharmaceutical manufacturers Ensuring quality of temperature-controlled products during transportation to county-level destinations or under extreme weather conditions Leveraging win-win partnerships with 3PL/4PL operators and other pharma companies to ensure a cost-effective and operationally-sound logistics Managing New GMP and Pharmaceutical Manufacturing Excellence Pharma manufacturing landscape Initiatives to reduce tech transfer costs, and improve location and operational flexibility Capitalizing on continuous manufacturing Establishing a quality agreement with a unified approach for all suppliers Assessing internal quality system effectiveness Closing Remarks from the Chair and Close of Day

4 14 th Annual China Pharma, Life Science & Healthcare Industry Summit & Exhibition DAY TWO Friday 17 th April, Registration & Morning Tea Opening Address from the Chairman REGULATORY UPDATE China s Healthcare System Reform: New Policies, Initiatives and Implementations in 2015/16 Updating on new policy initiatives, legislations and regulatory measures Drug demand estimate from the enhancement of the EDL system and the new rural collaboration medical system Drug reimbursement and hospital procurement system: where are they heading Public hospital reform and foreign investment in medical institutions in China: Implications for the pharma industry National Health and Family Planning Commission Key Focus of Drug Pricing Administration in 2015 National Development & Reform Commission KEYNOTE ADDRESS China Hospital Market Potential Estimate, Physician Access Strategies and New Successful SFE/Commercial Models How will the sales model evolve in the changing business environment Optimising drug pricing and patient access strategies in an age of austerity Beyond hospital targeting and segmentation: modelling and forecasting Sales force optimisation: Balance over-expanding vs. missed opportunity, broad vs. focus Building a robust sales force while keeping it flexible to allow for changes in local environment Hospital Drug Tendering: Future Policy Trends and Industry Moves Morning Refreshment & Network Break Physicians' Social Networks as a Strategic New Engagement Channel: Opportunities in China Physicians' social networks as a global phenomenon How Chinese physicians view the social networks in regard to their professional practice How pharma can leverage physicians' social networks to transform its relationship with the medical profession Taxonomies and partnership options Key learning from first movers Why multi-channel engagement is the only longterm option for China Application of Big Data in Accelerating Pharma Access and Commercial Operations Tapping into China s Broad Market Analysing China's community healthcare market and its potential opportunities Specific strategies and their potential utility by domestic players vs. global pharma Proven tactics employed by international companies who've made the effort to "go west" Networking Lunch KEY SEGMENT OUTLOOK & STRATEGIES China API and Generics Market Strategies Outlook of China s generic medicines market and changing regulations Challenges from and responses to competitive entries of originators Market entry optimisation: challenges in China How to build sustainable API/generic portfolio for the domestic and global markets Pre-emptive launching vs. the legal costs in aggressively pursuing market share Marketing branded generic drugs in China Successful out-licensing strategies Exploring Successful Strategies and Models for Biopharmaceutical The biopharma industry in China: Evolving business models, industry expansion vs. capital expansion, and IP right protection issues Impact from bioinformatics, drug licensing and alliance management in China Latest biopharma technologies, innovations on protein & gene pharmaceuticals and intermediates Strategies for moving early stage biotech to the growth phase of the life cycle Future outlook and investment/exit strategies Winning in China s Consumer Healthcare Market Understanding Chinese consumer behaviour when purchasing OTC medicines How to manage key OTC registration issues to expedite product launch Overcoming barriers to establish your OTC brands vs. competitive practices Expanding OTC business from developing distribution model to crafting point-of-sales strategies Addressing increasing encroachment from generics TCM & Plants Extracts Development in China Challenges and opportunities for TCMs in China vs. global market Safety administration and appraisal requirements for TCMs/TCM injections Development and innovation for plant extracts Quality control solutions for TCM and plant extract products US FDA Dietary Supplement Regulation and cgmp certification on plant extracts Afternoon Refreshment & Networking Break Drug Patent Application & IPR Protection in China: New Developments and Requirements PANEL DISCUSSION Managing Distribution Networks and Channel Strategies in a Changing Business and Regulatory Environment Closing Remarks from the Chair and End of Summit

5 14 th Annual China Pharma, Life Science & Healthcare Industry Summit & Exhibition SPONSORS Your Organization as Partner of Choice Custom-tailored Marketing Solutions Trade shows are out. Mass marketing is out. Traditional advertising is out. There's a huge shift toward targeted, segmented marketing and THAT is exactly what CPHIS provides. If you want access to the top professionals in China s pharmaceutical, life science & healthcare industry, invest in CPHIS 2015, we can create custom packages for budgets of any size. We promise to deliver results you can measure. As a business to business professional, you recognize how challenging it is to navigate through to the actual decision-makers. Our delicately-designed events attract attendance by top level professionals across industries and functions. CPHIS prides itself on delivering content of the highest quality, focusing on business strategy, market share and brand performance. We guarantee: Custom designed packages to match your budget and marketing objectives Face-to-face interaction and networking with top decision makers in a low pressure environment Opportunities to demonstrate your expertise through noncommercial presentations Extensive brand exposure through promotion of your company within an extensive integrated marketing campaign Positioning above your competition Strategically designed exhibit areas for optimum traffic 4 Key Reasons to Sponsor Strategic exposure and branding driven events with access to hundreds of qualified decision makers Effective platform to position products to key decision makers from a target audience in a short period of time Opportunity for face-to-face contact with key buyers at a competitive cost per contact and timely manner Ability to access numerous contacts in an environment conducive to conduct business CPHIS 2015 offers solution providers a variety of ways to meet their sales, marketing and business development objectives and to achieve their corporate targets. By concentrating an exhibition, conference and product demonstrations in one place, buyers from the entire region will use this opportunity to improve their awareness of the latest products, services, techniques and trends in their specific sector. CPHIS 2015 will assist all attendees in meeting the current and future challenges in the pharma, life science & healthcare industry. Access to post-conference feedback Our attendees seek your products and services. Together we can provide them with a one-stop-shop for all their marketing and business needs. Book & Secure Your Best Exhibition Area C O N F E R E N C E Coffee, Tea & Refreshment Area Exhibition Area Registration Platinum Booth Gold Booth Silver Booth Exhibitor Booth Elevator Reserved Reserve Your Seats Today Tel: Fax: davidl@gicsummits.com

6 14 th Annual China Pharma, Life Science & Healthcare Industry Summit & Exhibition 2015 年第十四届中国制药行业峰会暨展览 14 th CPHIS Shanghai China ORGANISER: Global Intelligence Communications Please return this form to David Liu Fax No: address: DATE: 16 th & 17 th April, 2015 (Main Conference) 2015 年 4 月 日 ( 主会议 ) VENUE: Shanghai, China 中国上海 REGISTRATION FORM 登记合同 Name/ 姓名 : Position/ 职位 : / 电子信箱 : Name/ 姓名 : Position/ 职位 : / 电子信箱 : Name/ 姓名 : Position/ 职位 : / 电子信箱 : Organisation/ 机构 : Address/ 地址 : Postcode/ 邮编 : Tel/ 电话 : Fax/ 传真 : Authorisation 授权 Name/ 姓名 : Position/ 职位 : Date/ 日期 : Signature/ 签名 : (This booking is invalid without a signature 本定单签名有效 ) Registration & Level of Participation 参会确认及参会形式 Sponsorship: Participate as a sponsor to enjoy tailored marketing exposure & business development opportunities from the event. 赞助 : 作为铂金 黄金或展览赞助商参与本次峰会, 获得针对您目标市场的最大宣传 展览 演讲以及客户拓展机会 Delegate: US$ 2,095/RMB 12,800/ Person (Fee is inclusive of a set of conference documentation, refreshments, lunch & access to all event activities). 参会 : 每人 2,095 美元 / 人民币 12,800 元 ( 包括资料 茶点 午宴及参与两天全部活动 ) Membership: US$3,595/RMB 22,000/Person for attending this event free of charge plus one year admission to all GIC pharma related events 成为 VIP 会员 : 每人每年 3,595 美元 / 人民币 22,000 元 : 免费参加此次活动, 并可参加一年内所有 GIC 医药行业会议及活动 Documentation: If you are unable to attend the conference but wish to receive the conference documentation (US$ 650/RMB 4,000/ Set including postage and packing) 资料 : 如无法参会但希望得到会议资料, 请填写销售合同, 在本方框上打钩并回传 ( 每套 650 美元 / 人民币 4,000 元, 包括邮费和包裹费 ) Payment Method 付款方式 Confirmation of Registration 确认方法 Confirmation Letter/ 确认函 All paid registration will be confirmed in writing upon clearance of payment. Please contact us if you did not receive our confirmation one week from your fax out. 如您发出登记合同一周后仍未收到相关确认函, 请致电我们 Formal invoice/ 正式发票 After receiving the payment, a formal receipt will be issued to the client. 在收到您的会务费后, 将寄出正式发票 Cancellations 取消 By returning this completed form, the client hereby agrees that GIC will not be able to mitigate its losses for any less than 50% of the total contract value. Cancellation must be received 4 weeks before the event. Delegate substitutions are welcome at any time. 此填好的登记表回传 GIC 公司后立即生效 会前 4 星期内任何取消客户承担总合同费用 50% 您可以在会前任何时候替换参会人员 Indemnity: Should for any reason outside the control of GIC, the venue or speakers change, or the event be cancelled due to an act of terrorism, extreme weather conditions or industrial action, GIC shall endeavour to reschedule, but the client hereby indemnifies and holds GIC harmless from and against any and all costs, damages and expenses, including attorneys fees, which are incurred by the client. I m paying by T/T transfer/ bank transfer/ 我通过电汇 / 银行转账付款 Pay to: The Industrial and Commercial Bank of Shanghai, China Beneficiary: Global Intelligence Communications China Co., Ltd Account No.: SWIFT Code: ICBKCNBJSHI 请在回传此报名表格后五个工作日内付款至 : 帐户名称 : 上海泽锡商务信息咨询有限公司开户行 : 平安银行上海西南支行人民币帐号 : 开户行代码 : Please debit my credit card (non-domestic)/ 请借记信用卡 ( 非境内卡 )* * Visa/ 威士卡 Mastercard/ 万事达卡 American Express/ 美国运通卡 Card Holder s Name/ 持卡人姓名 : Card Number/ 卡号 : Signature/ 签名 : _ Expiry Date/ 有效期 : / * Additional information required to complete the payment via credit card 必须提供额外信息完成信用卡付款, 我们将与您联系